TARINTIS Trademark

Trademark Overview

On Thursday, November 12, 2020, a trademark application was filed for TARINTIS with the United States Patent and Trademark Office. The USPTO has given the TARINTIS trademark a serial number of 90315997. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 26, 2024. This trademark is owned by Pfizer Inc.. The TARINTIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
tarintis

General Information

Serial Number90315997
Word MarkTARINTIS
Filing DateThursday, November 12, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 26, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 25, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 12, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-219
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, November 16, 2020NEW APPLICATION ENTERED
Tuesday, January 12, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, April 21, 2021ASSIGNED TO EXAMINER
Thursday, April 22, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 5, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 25, 2021PUBLISHED FOR OPPOSITION
Tuesday, May 25, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 20, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 6, 2021SOU TEAS EXTENSION RECEIVED
Monday, December 6, 2021SOU EXTENSION 1 FILED
Monday, December 6, 2021SOU EXTENSION 1 GRANTED
Wednesday, December 8, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 6, 2022SOU TEAS EXTENSION RECEIVED
Monday, June 6, 2022SOU EXTENSION 2 FILED
Monday, June 6, 2022SOU EXTENSION 2 GRANTED
Wednesday, June 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 1, 2022SOU TEAS EXTENSION RECEIVED
Thursday, December 1, 2022SOU EXTENSION 3 FILED
Thursday, December 1, 2022SOU EXTENSION 3 GRANTED
Tuesday, December 6, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 27, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, March 27, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, March 27, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, March 27, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, March 27, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, June 1, 2023SOU TEAS EXTENSION RECEIVED
Thursday, June 1, 2023SOU EXTENSION 4 FILED
Thursday, June 1, 2023SOU EXTENSION 4 GRANTED
Saturday, June 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 4, 2023SOU TEAS EXTENSION RECEIVED
Monday, December 4, 2023SOU EXTENSION 5 FILED
Tuesday, December 12, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, December 13, 2023SOU EXTENSION 5 GRANTED
Thursday, December 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 26, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, August 26, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

tarintis preparations disorders pharmaceutical treatment hypertension pain stroke cancer growth bone